Biolinq

Biolinq is a biotechnology startup founded in 2012 in the United States that aims to revolutionize metabolic health monitoring with its biosensing platform. The company's innovative approach involves the use of an array of electrochemical sensors that are designed to be minimally invasive, providing a new biowearable experience. This technology enables continuous sensing of multiple analytes such as glucose, ketones, and lactate, offering users actionable insights into their metabolic health. In April 2024, Biolinq secured a significant $58.00M Venture Round investment from a diverse group of investors including RiverVest, Pegasus Tech Ventures, Senvest Capital, Aphelion Capital, Global Health Investment Corporation, Niterra Ventures, Taisho Pharmaceutical Holdings, Features Capital, Alpha Wave Ventures, and AXA Investment Managers. This funding injection signifies a strong show of confidence from the investor community in Biolinq's vision and technology. With a focus on biotechnology and healthcare industries, Biolinq is well-positioned to tap into the growing demand for innovative solutions in the health tech space. The company's commitment to creating a positive and creative work environment, as well as its dedication to the personal and professional growth of its team members, underscores its focus on fostering a strong internal culture. Looking to the future, Biolinq's ambitions extend to bringing biosensing and biowearables into the mainstream over the next 10 years, signaling its long-term vision and determination to make a significant impact in the healthcare technology sector.